445493-23-2 Usage
Description
11107B, also known as Pladienolide B, is a macrocyclic lactone compound isolated from Streptomyces platensis. It is a highly potent inhibitor of hypoxia signals and cancer cell proliferation, functioning by binding to the SF3b complex and blocking the spliceosome. This unique mechanism of action makes it a promising candidate for various pharmaceutical applications.
Uses
Used in Pharmaceutical Industry:
11107B is used as a potent cancer cell growth inhibitor for targeting the SF3B1 subunit of the spliceosome. Its ability to inhibit cancer cell proliferation and disrupt hypoxia signals makes it a valuable compound in the development of novel cancer therapies.
Used in Anticancer Applications:
11107B is employed as an anticancer agent, particularly effective against various types of cancer. Its unique mechanism of action allows it to target the spliceosome, which is involved in the regulation of gene expression and cell growth. This makes 11107B a promising candidate for the development of new cancer treatments and potentially overcoming drug resistance in certain cases.
Used in Drug Delivery Systems:
To enhance the efficacy and bioavailability of 11107B, researchers are exploring various drug delivery systems. These systems aim to improve the compound's delivery to cancer cells, potentially increasing its therapeutic outcomes and reducing side effects. Novel drug delivery systems, such as organic and metallic nanoparticles, are being investigated for their ability to carry and release 11107B in a controlled manner, optimizing its anticancer properties.
Check Digit Verification of cas no
The CAS Registry Mumber 445493-23-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 4,4,5,4,9 and 3 respectively; the second part has 2 digits, 2 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 445493-23:
(8*4)+(7*4)+(6*5)+(5*4)+(4*9)+(3*3)+(2*2)+(1*3)=162
162 % 10 = 2
So 445493-23-2 is a valid CAS Registry Number.
445493-23-2Relevant articles and documents
Expedient Total Syntheses of Pladienolide-Derived Spliceosome Modulators
Rhoades, Derek,Rheingold, Arnold L.,O'Malley, Bert W.,Wang, Jin
, p. 4915 - 4920 (2021/05/04)
Atom and step economical total syntheses of spliceosome modulating natural products pladienolides A and B are described. The strategic functionalization of an unsaturated macrolide precursor enabled the most concise syntheses of these natural products to date and provides convenient, flexible access to stereodefined macrolides to streamline medicinal chemistry explorations. Notably, this synthetic route does not depend on protecting group manipulations that traditionally define synthesis planning for polyhydroxylated natural products of polyketide origin. Its utility is further demonstrated by the enantioselective total synthesis of H3B-8800, a hitherto semisynthetic pladienolide-derived spliceosome modulator undergoing clinical trials for hematological malignancies.
Synthesis of pladienolide b and its 7-epimer with insights into the role of the allylic acetate
Mueller, Sarah,Sasse, Florenz,Maier, Martin E.
, p. 1025 - 1036 (2014/03/21)
Diastereomeric macrolactones 41 and 48, which are epimeric at C-7, were both prepared by a synthesis based on our previously developed route to the macrolactone core of pladienolide B. Both compounds contain all the functionality of the macrolactone core
Enantioselective total synthesis of pladienolide B: A potent spliceosome inhibitor
Ghosh, Arun K.,Anderson, David D.
, p. 4730 - 4733 (2013/01/15)
An enantioselective and convergent total synthesis of pladienolide B (1) is described. Pladienolide B binds to the SF3b complex of a spliceosome and inhibits mRNA splicing activity. The synthesis features an epoxide opening reaction, an asymmetric reduction of a β-keto ester, and a cross metathesis strategy for the side chain synthesis.
